CAS: 4105-38-8; (2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1(2H)-yl)Tetrahydrofuran-3,4-Diyl Diacetate

该化合物是合成核核素,在核酸研究中具有重要用途.它表现出更加稳定和耐抗核素的特性,使它更适合体外研究.这个化合物有助于改进核酸合成的净化和产量增加,为研究人员提供了复杂的分子生物学实验的可靠工具.

结构式图片

相似化合物

2140-76-3 58-96-8 26287-69-4

上下游产品

CAS号108-24-7 乙酸酐 | CAS号58-96-8 尿苷 | CAS号55003-25-3 (2R,3R,4R,5R)-2... | CAS号66-22-8 尿嘧啶 | CAS号13035-61-5 四乙酰核糖 | CAS号116393-66-9 N3-benzyloxymet... | CAS号67-56-1 甲醇 | CAS号3736-77-4 2,2'-脱水尿苷 | CAS号58-96-8 尿苷 | CAS号65-46-3 胞嘧啶核苷 | CAS号20724-73-6 2'-C-甲基胞嘧啶核苷 | CAS号957-75-5 5-溴尿苷 | CAS号2341-22-2 5-氟胞苷 | CAS号65-47-4 5'-三磷酸胞苷 | CAS号69075-42-9 5-乙炔啶(5-EU) | CAS号13007-43-7 N4,N4-Dimethylc... | CAS号1024-99-3 5-碘尿苷

合成工艺路线路线简述

  • 合成目标产物 2',3',5'-Tri-O-Acetyluridine 主要起始原料 1-Acetylimidazole And Uridine
  • (文献来源)合成步骤主要原料 1-Acetylimidazole 和 Uridine
1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-Hydroxymethyl-Tetrahydro-Furan-2-yl)-4-(2-Oxo-2H-Pyridin-1-yl)-1H-Pyrimidin-2-One置于吡啶,四甲基胍,4-硝基苯甲醛肟体系中,用 1,4-二氧六环,水 作为反应溶剂,化学反应 1.05H,反应生成 2',3',5'-三乙酰尿苷
参考文献:Zhou; Welch; Chattopadhyaya,Acta Chemica Scandinavica. Series B: Organic Chemistry And Biochemistry,1986,Vol. 40,# 10,P. 806-816
标题:Zhou; Welch; Chattopadhyaya,Acta Chemica Scandinavica. Series B: Organic Chemistry And Biochemistry,1986,Vol. 40,# 10,P. 806-816

海关参考信息

专利信息


专利号:US-6818633-B2
优先权日:2001-06-29
标题:Antiviral compounds and methods for synthesis and therapy
发明人:BALZARINI JAN M R; DE CLERCQ ERIK D A; HOLY ANTONIN
权利人:ACAD OF SCIENCE CZECH REPUBLIC; REGA STICHTING
摘要:Novel compounds are provided having formula (I)whereR1, R2, R3, R4, Z, X and * are defined herein. Also provided are antiviral methods for use and processes for synthesis of the compounds of formula (I).

专利号:US-2017283878-A1
优先权日:2015-12-11
标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
权利人:ACADEMIA SINICA
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

专利号:US-8734846-B2
优先权日:2008-06-16
标 题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
发明人:ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS
权利人:BIND BIOSCIENCES INC
摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

专利号:US-5200514-A
优先权日:1990-01-19
标 题 :Synthesis of 2'-deoxypyrimidine nucleosides
发明人:CHU CHUNG K
权利人:UNIV GEORGIA RES FOUND
摘要:A method for the preparation of 2'-deoxynucleosides and 2',3'-dideoxy-2',3'-didehydronucleosides that includes the step of reacting a nucleoside having hydroxyl groups in the 2' and 3' positions with a mixture of acyl bromide or chloride and HX, wherein X is Br or Cl, at moderate temperature, to give a haloacyl nucleoside derivative that can be deprotected and reduced to form the desired compound.

专利号:US-2008214827-A1
优先权日:2004-02-03
标 题:Synthesis of Cyanoimino-Benzoimidazoles
发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
权利人:EURO CELTIQUE SA
摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.
新乡拓新药业股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.tuoxinchem.com
电话: 0373-6351927 3511287👤
📞新乡拓新药业股份有限公司 ⚠️参考联系方式

销售电话:0373-6351927 3511287
邮箱:xxzy@tuoxinchem.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
上海祥耕科技发展有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.sharingtechcn.com
电话: 0086 (21) 6049-5188👤
📞上海祥耕科技发展有限公司 ⚠️参考联系方式

销售电话:0086 (21) 6049-5188
邮箱:sharing@sharingtechcn.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
湖北鸿鑫瑞宇精细化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.hbhxry.com
企业联系电话:15307120296;13477033894👤
📞湖北鸿鑫瑞宇精细化工有限公司 ⚠️参考联系方式
联系人:陈经理
电话:15307120296;13477033894
手机:18164064948
传真:027-65526669
邮箱:2016269472@qq.com
通信地址: 武汉市东湖高新技术开发区关东园路​
邮编: 430000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:武汉市东湖高新技术开发区关东园路​
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
新乡市丰越新材料有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.tianfengchem.com
企业联系电话:13837300766👤
📞新乡市丰越新材料有限公司 ⚠️参考联系方式
联系人:李女士
电话:13837300766
手机:13837300766
传真:0373-2513858
邮箱:tianfeng@tianfengchem.com
通信地址: 新乡市环宇大道东侧
邮编: 453002
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:新乡市环宇大道东侧
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Lampropoulou DI, Laschos K, Amylidi AL, Angelaki A, Soupos N, Boumpoucheropoulos S, Papadopoulou E, Nanou E, Zidianakis V, Nasioulas G, Fildissis G, Aravantinos G. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA? J Oncol Pharm Pract. 2019 Aug
5:1078155219865597. doi: 10.1177/1078155219865597. [Epub ahead of print] doi: 10.1177/2050313X18786405. eCollection 2018.
3: Garcia RAG, Saydoff JA, Bamat MK, von Borstel RW. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency. Toxicol Appl Pharmacol. 2018 Aug 15;353:67-73. doi: 10.1016/j.taap.2018.06.012. Epub 2018 Jun 13. doi: 10.1177/1078155217732141. Epub 2017 Sep 26. Review. e7-802.e8. doi: 10.1016/j.ajem.2016.11.038. Epub 2016 Nov 15. doi: 10.1002/phar.1841. Epub 2016 Nov 4. doi: 10.1002/cncr.30321. Epub 2016 Sep 13.

合成参考文献


参考文献:10.1037/1064-1297.16.3.199
摘要:Jensen JE, Daniels M, Haws C, Bolo NR, Lyoo IK, Yoon SJ, Cohen BM, Stoll AL, Rusche JR, Renshaw PF. Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients. Experimental and Clinical Psychopharmacology. 2008;16(3):199–206. doi: 10.1037/1064-1297.16.3.199.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知